Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay

scientific article published on 13 May 2009

Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/CVI.00042-09
P932PMC publication ID2708396
P698PubMed publication ID19439523

P50authorLouis H. MillerQ1646045
Mark C PierceQ88672445
Gregory E.D. MullenQ114406008
Samuel E MoretzQ114406013
Ababacar DioufQ122675166
Michael P. FayQ48691498
Kazutoyo MiuraQ66876252
Carole A LongQ66908908
Ruth D EllisQ72369361
P2093author name stringHong Zhou
Laura B Martin
P2860cites workSafety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adultsQ21144326
The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwideQ21563408
Invasion of red blood cells by malaria parasitesQ29618806
Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan childrenQ33264521
Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trialQ33264523
Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malariaQ33281394
The importance of human FcgammaRI in mediating protection to malariaQ33285037
Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult MaliansQ33302903
Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian childrenQ33319552
Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malariaQ33359552
Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adultsQ33380213
Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.Q33394245
Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malariaQ33788306
Specificity of the protective antibody response to apical membrane antigen 1Q34007362
In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic responseQ34260615
Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activityQ34975629
Band 3 is a host receptor binding merozoite surface protein 1 during thePlasmodium falciparuminvasion of erythrocytesQ34982236
In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunizedQ36314049
A review of human vaccine research and development: malariaQ36625367
Plasmodium falciparum malaria vaccines in developmentQ37103927
Intimate molecular interactions of P. falciparum merozoite proteins involved in invasion of red blood cells and their implications for vaccine designQ37246279
Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccinationQ37459461
Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria.Q39417737
Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.Q40144102
Characterization of a human reference standard for antibody to Plasmodium falciparum merozoite surface protein 1(42).Q40413012
Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cellsQ40582637
Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodiesQ41172326
MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectivesQ42605516
Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytesQ42938913
A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvantQ46423309
Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccineQ46852571
Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western KenyaQ46884256
Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of AfricaQ47309532
Gamma-globulin and acquired immunity to human malariaQ47957467
P433issue7
P921main subjectantibodyQ79460
Plasmodium falciparumQ311383
P304page(s)963-968
P577publication date2009-05-13
P1433published inClinical and Vaccine ImmunologyQ5133811
P1476titleAnti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay
P478volume16